Nitie yore mang'eny mag thiedho kansa mar prostate, kaluwore gi okang' ma tuwo mar kansa okaloe, kaachiel gi chal mar ng'ato, koda gik ma ng'ato ohero timo.
Moko kuom yore ma ji mang'eny tiyogo gin kaka:
1. Chenro mar rito tuo mar kansa: Chenro ma kamano oriwo ng'iyo tuwo mar kansa adimba kokalo kuom nonro kod nonro mitimo kinde ka kinde, kar chako thieth mapiyo.
Onyalo bedo maber ne chwo ma nigi tuwo mar kansa mar prostate ma nigi hinyruok matin.
2. Tiyo gi yore mag yeng'o: Tiyo gi yore mag yeng'o e golo prostate.
Inyalo time e yor yeng'o kata e yor laparoscopy (kitiyo gi gik matindo tindo kod gige tich mopogore opogore).
3. Tiyo gi radiation: Tiyo gi radiation ma nigi teko mang'eny e nego ng'injo mag kansa.
Onyalo tigo oko mar del (kuom masin man oko mar del) kata ei del (kuom implant moket machiegni gi ng'ol).
4. Tiyo gi hormone: Tiyo gi hormone mag chwo (androgens) e del, nyalo duoko chien kata chungo dongruok mar kansa mar prostate.
Inyalo ti kode kende kata kanyachiel gi yore mamoko mag thiedho tuoche.
5. Chemotherapy: Chenro mar thiethni tiyo gi yedhe ma nego ng'injo mag kansa.
Inyalo ti kode e thiedho tuwo mar kansa mar prostate moselandore e fuonde mamoko mag del.
6. Immunotherapy: Chenro ma kamano konyo ng'ato kedo gi tuwo mar kansa.
Inyalo ti kode e thiedho kansa mar prostate mosedongo ma pok odwoko e yore mamoko mag thieth.
7. Tiyo gi yadhno e yo mochanore maber: Yadhno tiyo gi ng'injo kata protein moko makonyo ng'injo mag kansa dongo kendo dak.
Inyalo ti kode e thiedho kansa mar prostate mosedongo ma pok odwoko e yore mamoko mag thieth.
8. Cryotherapy: Chenro ma kamano tiyo gi liet mang'eny ahinya e ng'ich kendo nego ng'injo mag kansa.
Inyalo ti kode e thiedho kansa mar prostate e okang ' motelo, kata e thiedho kansa moseduogo bang ' thieth mamoko.
9. High-intensity focused ultrasound (HIFU): Chenro mar thiethni tiyo gi dwol ma nigi dwol mamalo e miyo ng'ato obed mang'ich kendo ketho ng'injo mag kansa.
Inyalo ti kode e thiedho kansa mar prostate e okang ' motelo, kata e thiedho kansa moseduogo bang ' thieth mamoko.
10. Rito e yo motang': Yo ma kamano oriwo ng'iyo kansa adimba kuom timo nonro kendo timo nonro kinde ka kinde, to ok ochak thiedho ng'ato mak mana ka ranyisi mag tuwono nenore kata lokore.
Onyalo bedo maber ne chwo ma hikgi ng'eny ma nigi kansa mar prostate ma dongo mos kod tuoche mamoko madongo.
Dwarore ni iwuo kuom yore duto mag thieth gi laktar mondo ing'e gima ber monego itim e ng'ato ka ng'ato.
Wang Y, Chen J, Wu Z, Ding W, Gao S, Gao Y, Xu C: Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. Br J Pharmacol. 2021, 178 (2): 239-261.
Talkar SS, Patravale VB: Gene Therapy for Prostate Cancer: A Review. Endocr Metab Immune Disord Drug Targets. 2021, 21 (3): 385-396.
Šamija I, Fröbe A: CHALLENGES IN MANIPULATING IMMUNE SYSTEM TO TREAT PROSTATE CANCER. Acta Clin Croat. 2019, 58 (Suppl 2): 76-81.
Akaza H, Hinotsu S, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Hirao Y, Murai M, Yamanaka H, Namiki M: The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. J Urol. 2006, 176 (6 Pt 2): S47-9.
Abraham-Miranda J, Awasthi S, Yamoah K: Immunologic disparities in prostate cancer between American men of African and European descent. Crit Rev Oncol Hematol. 2021, 164 (): 103426.
de Vrij J, Willemsen RA, Lindholm L, Hoeben RC, Bangma CH, Barber C, Behr JP, Briggs S, Carlisle R, Cheng WS, Dautzenberg IJ, de Ridder C, Dzojic H, Erbacher P, Essand M, Fisher K, Frazier A, Georgopoulos LJ, Jennings I, Kochanek S, Koppers-Lalic D, Kraaij R, Kreppel F, Magnusson M, Maitland N, Neuberg P, Nugent R, Ogris M, Remy JS, Scaife M, Schenk-Braat E, Schooten E, Seymour L, Slade M, Szyjanowicz P, Totterman T, Uil TG, Ulbrich K, van der Weel L, van Weerden W, Wagner E, Zuber G: Adenovirus-derived vectors for prostate cancer gene therapy. Hum Gene Ther. 2010, 21 (7): 795-805.
Lee E, Ha S, Logan SK: Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells. PLoS One. 2015, 10 (10): e0141589.
Ng'at ma kwedo weche mag thieth
Websaitni olos mondo okony ji ng'eyo weche mag thieth, to ok mondo okonygi ng'eyo kaka ginyalo tiyo gi yore mag thieth.
Weche mochiw ok onego oti kodgi e fwenyo kata thiedho tuwo moro, kendo jogo madwaro ng'eyo kaka ginyalo thiedho tuwo moro, onego owuo gi laktar molony.
Ng'e ni neural net ma chiwo dwoko mag penjo, ok en makare ahinya sama iwuoyo kuom kwan mag ji, kaka kwan mar joma nigi tuwo moro.
Kinde duto many paro mar laktar kata ng'at machielo molony e weche thieth e wi tuwo moro. Kik iket kiawa kuom paro mar laktar kata duoko chien kwayo mar thieth nikech gimoro ma isomo e websaitni. Kapo ni iparo ni inyalo bedo gi chandruok mar thieth, luong 911 kata dhi e od thieth machiegni mapiyo. Onge tudruok moro amora e kind laktar gi jatuwo ma yudore e websaitni kata e tiyo kode. BioMedLib kata jotichne, kata ng'ato ang'ata ma konyo e websaitni, ok nyal chiwo paro moro amora, kata ma ok ong'ere, e wi weche ma yudore e websaitni kata e tiyo kode.
Ng'eyo ni ng'ato nigi ratiro mar timo gik moko
Digital Millennium Copyright Act mar 1998, 17 U.S.C. § 512 (the DMCA) chiwo yore mag kony ne joma nigi ratiro mag ndiko ma paro ni weche ma yudore e Intanet ketho ratiro ma gin-go kaluwore gi chike mag ndiko mag piny Amerka.
Kapo ni iyie gi adiera ni weche moro amora ma yudore e websait marwa kata e tijewa ketho ratiro ma in-go mar ndiko weche, in (kata ng'at mochung'ne) inyalo oronwa barua ka ikwayo ni ogol weche ma yudore e websaitno, kata mondo ogeng' ng'ato kik yudgi.
Weche ma ng'ato onego owach nyaka oor e yo mondik kokalo kuom e-mail (ne "Contact" e wi adres mar e-mail).
DMCA dwaro ni ng'eyo ma in-go kuom ketho chik mar copyrights oting'o weche maluwogi: (1) ler mar tij copyrights ma ikwano ni oketho; (2) ler mar weche ma ikwano ni oketho chik mar copyrights kod weche moromo mondo okonywa ng'eyo kama wechego nitie; (3) weche mag tudruok kodi, moriwo adresni, namba mar simo kod adres mar email; (4) weche ma in-go manyiso ni in gi yie maber ni weche ma ondik e yo ma ikwedo ok oyie gi jal ma nigi ratiro mar copyrights, kata gi ng'at mochung'ne, kata gi chik moro amora;
(5) weche ma in iwuon iwacho, ma iketo e bwo buch kuong'ruok, ni weche manie kalatasno gin adier, kendo ni in gi teko mar tiyo gi ratiro mag ndiko ma ji wacho ni oketh;
(6) kod signature mar ng'at ma nigi ratiro mar timo gik moko, kata ng'at ma nigi ratiro mar timo gik moko e lo ng'at ma nigi ratiro mar timo gik moko.
Ka ok iketo weche duto monyis malo kae, mano nyalo miyo idonj e kesno bang'e.
Wuo gi ng'at machielo
Ka in gi penjo kata paro moro amora, yie iornwa e-mail.
How to treat prostate cancer?
There are several treatment options available for prostate cancer, depending on the stage and aggressiveness of the cancer, as well as the patient's overall health and personal preferences.
Some common treatments include:
1. Active surveillance: This approach involves closely monitoring the cancer with regular checkups and tests, rather than immediately starting treatment.
It may be suitable for men with low-risk prostate cancer.
2. Surgery: A prostatectomy is a surgical procedure to remove the prostate gland.
It can be done through open surgery or laparoscopically (using small incisions and specialized tools).
3. Radiation therapy: This treatment uses high-energy radiation to kill cancer cells.
It can be delivered externally (from a machine outside the body) or internally (through implants placed near the tumor).
4. Hormone therapy: This treatment reduces the levels of male hormones (androgens) in the body, which can slow or stop the growth of prostate cancer.
It can be used alone or in combination with other treatments.
5. Chemotherapy: This treatment uses drugs to kill cancer cells.
It may be used for advanced prostate cancer that has spread to other parts of the body.
6. Immunotherapy: This treatment helps the immune system fight cancer.
It may be used for advanced prostate cancer that has not responded to other treatments.
7. Targeted therapy: This treatment targets specific genes or proteins that help cancer cells grow and survive.
It may be used for advanced prostate cancer that has not responded to other treatments.
8. Cryotherapy: This treatment uses extreme cold to freeze and kill cancer cells.
It may be used for early-stage prostate cancer or for cancer that has come back after other treatments.
9. High-intensity focused ultrasound (HIFU): This treatment uses high-frequency sound waves to heat and destroy cancer cells.
It may be used for early-stage prostate cancer or for cancer that has come back after other treatments.
10. Watchful waiting: This approach involves closely monitoring the cancer with regular checkups and tests, but not starting treatment unless symptoms appear or change.
It may be suitable for older men with slow-growing prostate cancer and other serious health conditions.
It is important to discuss all treatment options with a healthcare team to determine the best course of action for each individual case.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
Chiegni ni
BioMedLib tiyo gi kompyuta ma tiyo gi masinde (ma iluongo ni machine-learning algorithms) e loso penjo gi dwoko.
Ne wachako gi buge milion 35 mag weche thieth miluongo ni PubMed/Medline. Bende, ne wachako gi buge mag RefinedWeb.
